Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-542X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer ; volume:19 ; number:1 ; day:9 ; month:2 ; year:2017 ; pages:1-12 ; date:12.2017
Breast cancer research ; 19, Heft 1 (9.2.2017), 1-12, 12.2017

Schlagwort
Krebs
Onkologie

Urheber
Bianchini, Giampaolo
Beteiligte Personen und Organisationen
Kiermaier, Astrid
Bianchi, Giulia Valeria
Im, Young-Hyuck
Pieńkowski, Tadeusz
Liu, Mei-Ching
Tseng, Ling-Ming
Dowsett, Mitch
Zabaglo, Lila
Kirk, Sarah
Szado, Tania
Eng-Wong, Jennifer
Amler, Lukas C.
Valagussa, Pinuccia
Gianni, Luca
SpringerLink (Online service)

DOI
10.1186/s13058-017-0806-9
URN
urn:nbn:de:1111-201703057155
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:50 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Bianchini, Giampaolo
  • Kiermaier, Astrid
  • Bianchi, Giulia Valeria
  • Im, Young-Hyuck
  • Pieńkowski, Tadeusz
  • Liu, Mei-Ching
  • Tseng, Ling-Ming
  • Dowsett, Mitch
  • Zabaglo, Lila
  • Kirk, Sarah
  • Szado, Tania
  • Eng-Wong, Jennifer
  • Amler, Lukas C.
  • Valagussa, Pinuccia
  • Gianni, Luca
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert / lokal rezidiviert; in Kombination mit Docetaxel) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert / lokal rezidiviert; in Kombination mit Docetaxel) : Nutzenbewertung gemäß § 35a SGB V

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Verbundene Objekte